2月7日,中国生物制药下属北京泰德制药双喜临门,其自主研发的洛索洛芬钠凝胶贴膏(商品名:得舒平®)与妥洛特罗贴剂(商品名:德瑞妥®)同日获得生产批件。这不仅标志着泰德制药在呼吸和镇痛治疗领域的重大突破,也突显了其作为国内最大外用贴剂企业的龙头地位。本次泰德制药获批的洛索洛芬钠作为非甾体抗炎药物,自1986年口服制剂问世便广泛应用于临床,具有解热、镇痛、抗炎功效。泰德制药凭借自主搭建的凝胶贴膏技术...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.